for females ages 18 years and up (full criteria)
at San Francisco, California
study started
estimated completion:
Anand Dhruva



The purpose of this study is to develop and test a 12-month Integrative Medicine intervention based on Ayurvedic medicine in recent breast cancer survivors.

Official Title

Developing an Integrative Ayurvedic Intervention for Breast Cancer Survivorship


Cancer associated symptoms and impaired quality of life remain significant problems for patients despite advances in cancer treatment. Few effective treatment options exist for these symptoms. Integrative medicine is rising in popularity in the United States; however, few integrative medicine modalities have been rigorously studied. Ayurveda, a whole system of medicine that originated in the Indian subcontinent, has its own system of diagnostics and therapeutics, and among its strengths are wellness and prevention. The investigators aim to perform a prospective single arm clinical study of a manualized Ayurvedic approach in breast cancer survivors with impaired quality of life. Specifically, the investigators aim to refine the manualized Ayurvedic intervention; to assess feasibility; and to determine whether clinically meaningful effects can be achieved with the intervention.


Breast Cancer Breast Neoplasms Individualized Integrative Medicine Intervention


You can join if…

Open to females ages 18 years and up

  • Female breast cancer survivor who is over 1 month and less than 24 months beyond the completion of primary therapy (surgery, radiation, and chemotherapy)
  • Having received chemotherapy as part of their primary therapy for breast cancer
  • Be in complete remission
  • Aged 18 years or older
  • Able to read, write, and understand English
  • Karnofsky Performance Status (KPS) greater than or equal to 60
  • Have impaired quality of life
  • Ability to give informed consent

You CAN'T join if...

  • Having received Ayurvedic treatment within 6 months of study enrollment
  • Receiving chemotherapy or radiotherapy at the time of study enrollment. Anti-her2 directed therapy is not exclusionary.
  • Being within 1 month (before or after) of surgery for breast cancer (including breast reconstructive surgery). Smaller surgical procedures such as implant exchange are not exclusionary.
  • Patients on adjuvant hormone therapy for less than 2 months
  • Have surgery for breast cancer or breast reconstructive surgery planned during the initial 6 month study period. Smaller surgical procedures such as implant exchange are not exclusionary.


  • University of California, San Francisco, Osher Center for Integrative Medicine
    San Francisco California 94115 United States

Lead Scientist

  • Anand Dhruva
    Associate Professor, Medicine. Authored (or co-authored) 45 research publications


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Last Updated